Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
- DOI
- Language of the publication
- English
- Date
- 2023-09-27
- Type
- Article
- Author(s)
- Yau, Kevin
- Kurtesi, Alexandra
- Qi, Freda
- Delgado-Brand, Melanie
- Tursun, Tulunay R.
- Hu, Queenie
- Dhruve, Miten
- Kandel, Christopher
- Enilama, Omosomi
- Levin, Adeera
- Jiang, Yidi
- Hardy, W. Rod
- Yuen, Darren A.
- Perl, Jeffrey
- Chan, Christopher T.
- Leis, Jerome A.
- Oliver, Matthew J.
- Colwill, Karen
- Gingras, Anne-Claude
- Hladunewich, Michelle A.
- Publisher
- Nature Portfolio
Abstract
Neutralization of Omicron subvariants by different bivalent vaccines has not been well evaluated. This study characterizes neutralization against Omicron subvariants in 98 individuals on dialysis or with a kidney transplant receiving the BNT162b2 (BA.4/BA.5) or mRNA-1273 (BA.1) bivalent COVID-19 vaccine. Neutralization against Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 increased by 8-fold one month following bivalent vaccination. In comparison to wild-type (D614G), neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization was not significantly different by bivalent vaccine type for wild-type (D614G) (P = 0.48), BA.1 (P = 0.21), BA.5 (P = 0.07), BQ.1.1 (P = 0.10), nor XBB.1.5 (P = 0.10). Hybrid immunity conferred higher neutralizing antibodies against all Omicron subvariants. This study provides evidence that BNT162b2 (BA.4/BA.5) and mRNA-1273 (BA.1) induce similar neutralization against Omicron subvariants, even when antigenically divergent from the circulating variant.
Subject
- Health
Rights
Peer review
Yes
Open access level
Gold
Identifiers
- ISSN
- 2041-1723
Article
- Journal title
- Nature Communications
- Journal volume
- 14
- Journal issue
- 1
- Article number
- 6041
- Accepted date
- 2023-09-14
- Submitted date
- 2023-04-27
Citation(s)
Yau, K., Kurtesi, A., Qi, F. et al. Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease. Nat Commun 14, 6041 (2023). https://doi.org/10.1038/s41467-023-41678-9